Skip to main content
Wockhardt Ltd logo

Wockhardt Ltd — Investor Relations & Filings

Ticker · WOCKPHARMA ISIN · INE049B01025 LEI · 3358001OC2OX7OZAHZ33 BSE.NS Manufacturing
Open in API
Filings indexed 861 across all filing types
Latest filing 2022-03-22 Capital/Financing Update
Country IN India
Listing BSE.NS WOCKPHARMA

About Wockhardt Ltd

https://www.wockhardt.com/

Wockhardt Ltd is a research-driven global organization focused on the development and manufacturing of formulations, biopharmaceuticals, and active pharmaceutical ingredients (APIs). The company maintains a specialized focus on drug discovery, particularly in the field of anti-infectives and New Chemical Entities (NCEs) aimed at addressing antimicrobial resistance. Its therapeutic portfolio encompasses diverse areas such as diabetes, nephrology, cardiology, and respiratory health. With a strong emphasis on research and development, the company operates multiple manufacturing facilities that comply with international regulatory standards. Wockhardt provides medical solutions across various international markets, utilizing its expertise in complex chemistry and biotechnology to address unmet clinical needs.

Recent filings

Filing Released Lang Actions
Newspaper Advertisements
Capital/Financing Update Classification · 95% confidence The document is a detailed communication from Wockhardt Limited to stock exchanges regarding the issue of up to 33,244,650 fully paid-up equity shares on a rights basis. It references the Letter of Offer dated March 4, 2022, and includes information about the dispatch of the Abridged Letter of Offer, Application Form, and Rights Entitlement Letter. The content focuses on the rights issue process, regulatory compliance under SEBI ICDR Regulations, and publication of advertisements related to the rights issue. There is no indication of financial statements, audit opinions, earnings data, or management discussion of financial results. Instead, the document is an official announcement about a capital raising activity through a rights issue. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2022-03-22 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Wockhardt Limited regarding a collaboration agreement with Serum Life Sciences UK for manufacturing vaccines. It includes details about the contract terms, parties involved, and the nature of the collaboration. The document references compliance with SEBI Listing Regulations and includes a press release. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The content is primarily an update on a significant business collaboration and contract award, which fits the category of a regulatory announcement about a material contract or business update. It is not an earnings release, annual report, or management discussion. The document is longer than 5,000 characters and contains substantive information about the contract and collaboration, not just a brief notice or report publication announcement. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2022-03-20 English
Awarding orders/contract
Regulatory Filings Classification · 95% confidence The document is a formal announcement addressed to stock exchanges (BSE and NSE) regarding a collaboration agreement between Wockhardt Limited and Serum Life Sciences UK for manufacturing vaccines. It includes details pursuant to Regulation 30 of the SEBI Listing Regulations, which governs disclosure of material events or information by listed entities. The document contains a press release and an annexure with contract details but does not include any financial statements, quarterly or annual results, or management discussion and analysis. It is not a report but an announcement of a significant business collaboration and contract award. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and disclosures that do not fit other specific categories.
2022-03-20 English
General updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about a scheduled virtual Regional Broker's Meet to update on recent business developments. It references SEBI regulations and provides meeting details but does not contain any financial data, report content, or detailed presentation materials. The document length is only 1092 characters, indicating it is a brief announcement rather than a full report or transcript. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance notices that do not fit other categories.
2022-03-18 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the National Institutes of Health (NIH), USA, will conduct a Phase 1 clinical trial of Wockhardt's novel antibiotic WCK 6777. It contains no financial data, no regulatory filings, no voting results, no management changes, no earnings or annual report content. It is a corporate announcement about a clinical trial and drug development progress. The document is not a report, nor an announcement of a report publication. It is a press release related to company developments, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-03-16 English
Newspaper Advertisements
Capital/Financing Update Classification · 95% confidence The document is a letter from Wockhardt Limited addressed to stock exchanges (BSE and NSE) regarding the issue of up to 33,244,650 fully paid-up equity shares on a rights basis. It references the Letter of Offer dated March 4, 2022, and mentions the publication of an advertisement related to the rights issue. The content focuses on the announcement and procedural details of a capital raising event (rights issue) under SEBI regulations. There are no financial statements or detailed financial performance data present. The document is essentially an update on a capital raising activity and related regulatory compliance, not a full financial report or earnings release. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 4540 characters, which is consistent with an announcement rather than a full report.
2022-03-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.